|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/4162 | |
| A61K 31/4375 | |||
| C07D 471/04 | |||
| C07D 498/04 |
| (11) | Patento numeris | 3074011 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 14863514.7 |
| Europos patento paraiškos padavimo data | 2014-11-21 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-10-05 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-07-24 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2014/066759 |
| Data | 2014-11-21 |
| (87) | Numeris | WO 2015/077530 |
| Data | 2015-05-28 |
| (30) | Numeris | Data | Šalis |
| 201361908333 P | 2013-11-25 | US | |
| 201461985035 P | 2014-04-28 | US |
| (72) |
HUNT, Hazel, GB
WALTERS, Iain, GB
GOURDET, Benoit, GB
|
| (73) |
Corcept Therapeutics Incorporated,
149 Commonwealth Drive, Menlo Park, CA 94025,
US
|
| (54) | OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS |
| OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS |